A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Myeloproliferative Neoplasms Clinical Trial

Official title:

A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05444530
• Other study ID #: CR109149
• Secondary ID: 2021-006033-20VA
• Status: Recruiting
• Phase: Phase 1
• Start date: July 21, 2022
• Est. completion date: November 27, 2027

Study information

• Verified date: April 2024
• Source: Janssen Research & Development, LLC
• Contact: Study Contact
• Phone: 844-434-4210
• Email: Participate-In-This-Study[@]its.jnj.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: November 27, 2027
• Est. primary completion date: January 16, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be positive for a CALR (calreticulin) mutation: Type 1 or Type 2; Type 1-like, or Type 2-like may be considered with Sponsor approval; or positive for the JAK2V617F (Janus kinase 2 with valine 617 to phenylalanine mutation) mutation with HLA-A02:01 (human leukocyte antigens) per medical history or local testing
• Have an Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 or 2
• Have the following hematologic laboratory values: Leukocytes greater than or equal to (>=) 1.5*10^9 per liter, Neutrophils >=1.0*10^9 per liter, Platelets >=20*10^9 per liter, Hemoglobin greater than (>) 7 gram per deciliter (g/dL)
• Have the following chemistry laboratory values: Alanine aminotransferase (ALT): less than or equal to (<=) 3*upper limit of normal (ULN), Aspartate aminotransferase (AST): <=3*ULN, Total bilirubin: <=1.5*ULN, and glomerular filtration rate >=40 milliliter per minute (mL/min)
• A female participant of childbearing potential must agree to all the following during the study and for 6 months after the last dose of study treatment: use a barrier method of contraception, use a highly effective preferably user-independent method of contraception, not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction, not plan to become pregnant, not to breast-feed
• A male participant must agree to all the following during the study and for 90 days after the last dose of study treatment: wear a condom when engaging in any activity that allows for passage of ejaculate to another person, not to father a child, not to donate sperm or freeze for future use for the purpose of reproduction

Exclusion Criteria:

• History of any significant medical condition per investigators judgment (example:

severe asthma/chronic obstructive pulmonary disease (COPD), poorly regulated heart condition, insulin dependent diabetes mellitus)

• Serious known clinically relevant allergies or earlier anaphylactic reactions
• Currently pregnant or breastfeeding
• Prior treatment with any Janus kinase 1/2 (JAK1/2) inhibitor
• Known sensitivity or contraindications to the use of Ipilimumab per local prescribing information

Related Conditions & MeSH terms

• Myeloproliferative Disorders
• Myeloproliferative Neoplasms
• Neoplasms

Intervention

Biological:
• VAC85135
Participants will receive VAC85135 as IM injection.

Drug:
• Ipilimumab
Participants will receive Ipilimumab as IV infusion.

Locations

Country	Name	City	State
United Kingdom	Guy's and St Thomas' Hospital	London
United Kingdom	The Christie NHS Foundation Trust Christie Hospital	Manchester
United Kingdom	Churchill Hospital	Oxford
United States	University of Michigan	Ann Arbor	Michigan
United States	Cleveland Clinic	Cleveland	Ohio
United States	City of Hope	Duarte	California
United States	MD Anderson Cancer Center	Houston	Texas
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Rutgers University	Newark	New Jersey
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC	Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose-limiting Toxicity (DLT)	Number of participants with a DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. Toxicities will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.	Baseline (Day 1) up to Day 78
Primary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical product. AEs will be graded as Grade 1: Mild- asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate- minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4- Life-threatening consequences- urgent intervention indicated; Grade 5: Death related to AE.	Up to 79 weeks
Secondary	Number of Participants With Antigen-specific T-cell response	Number of participants with antigen-specific T-cell response will be reported.	Up to end of treatment (EOT) (Up to 64 weeks)
Secondary	Number of Participants With Overall Response per Revised Response Criteria by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) Consensus Report	Overall response will be measured by complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, progressive disease, stable disease and relapse as per the revised IWG-MRT and ELN response criteria for myelofibrosis (MF).	Up to 79 weeks
Secondary	Number of Participants Disease Response at Weeks 24, 48 and End of Treatment (EOT) per Modified IWG-MRT Criteria	Number of participants with disease response as per the modified IWG-MRT criteria will be reported.	Weeks 24, 48 and EOT (64 weeks)
Secondary	Number of Participants With Peripheral Blood Mutant Calreticulin (mutCALR) and Janus Kinase 2 With V617F Mutation (JAK2V617F) Allele Burden	Number of participants with peripheral blood mutCALR and JAK2V617F allele burden will be reported.	Up to end of treatment (EOT) (Up to 64 weeks)
Secondary	Number of Participants With Transfusion Burden	Number of participants with transfusion burden will be reported.	Up to end of treatment (EOT) (Up to 64 weeks)
Secondary	Number of Participants With Patient-reported Symptoms on Therapy	Number of participants with patient-reported symptoms on therapy will be reported.	Up to end of treatment (EOT) (Up to 64 weeks)
Secondary	Time to Progression of Myeloproliferative Neoplasms (MPNs)	Time to progression of MPNs (polycythemiavera [PV], essential thrombocythemia [ET], and primary myelofibrosis [PMF]) will be reported.	Up to end of treatment (EOT) (Up to 64 weeks)
Secondary	Time to Initiation of Next Therapy	Time to initiation of next therapy for myeloproliferative neoplasms (MPNs) will be reported.	Up to 79 weeks